加拿大国家疫苗安全网络:成人mRNA新冠疫苗主动安全性监测
加拿大国家疫苗安全网络(CANVAS)在成人两剂mRNA新冠疫苗接种期间开展主动安全性监测,纳入未接种对照组。接种后一周内健康事件风险高于对照,风险比从BNT162b2第一剂的2.3到mRNA-1273第二剂的7不等,多数症状自限;需急诊或住院的事件在mRNA-1273接种后显著增加,BNT162b2未见此差异。
要点
- 接种后一周内健康事件风险高于未接种对照,mRNA-1273第二剂风险比最高达7。
- 常见症状为疲劳/不适、头痛、发热和关节痛,多数自限。
- 需急诊或住院的事件在mRNA-1273接种后显著增加,BNT162b2未见。
核心结论
- 接种mRNA新冠疫苗后一周内自限性健康事件较未接种对照更常见,mRNA-1273第二剂频率最高。
- 需急诊就诊或住院的健康事件在mRNA-1273接种后较对照显著增加,BNT162b2未观察到此差异。
研究设计与样本
- CANVAS在加拿大7个省和地区开展队列研究,招募接种和未接种成人,接种者每剂后一周完成邮件调查,未接种对照在登记时完成。
- 第一剂后567,781人、第二剂后301,717人完成调查,未接种对照14,984人。
- 主要结局为导致缺勤(工作或学校)或需医疗咨询的健康事件,采用多变量回归分析。
主要发现
- 多变量分析中,接种后一周内健康事件风险高于对照,风险比从BNT162b2第一剂的2.3(95%CI 2.1–2.6)到mRNA-1273第二剂的7(95%CI 6.3–7.8)。
- 常见症状包括疲劳/不适、头痛、发热和关节痛,多数自限。
- 需急诊或住院的健康事件在mRNA-1273第一剂后(RR 2.1,95%CI 1.5–3.1)和mRNA-1273第二剂后(RR 2,95%CI 1.3–2.9)显著增加。
- BNT162b2接种后未观察到需急诊或住院健康事件的显著增加。
临床怎么用
- 向成人接种者告知mRNA新冠疫苗后一周内可能出现自限性健康事件,多数可自行缓解。
- 关注mRNA-1273接种后需急诊或住院事件的信号,接种后做好健康监测与就医指引。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Canadian National Vaccine Safety Network (CANVAS) conducted active vaccine safety surveillance during the two-dose primary COVID-19 mRNA vaccine rollout in Canadian adults and expanded on the findings of prior active safety surveillance studies by including an unvaccinated control group. In this cohort study, vaccinated and unvaccinated adults from 7 provinces and territories were recruited to complete emailed surveys one week after each vaccine dose (or at registration for unvaccinated controls). The primary outcome was a health event that resulted in missed work or school or required medical consultation. Multivariable regression models examined health events associated with the first and second doses of BNT162b2 (Pfizer) and mRNA-1273 (Moderna) vaccines. Surveys were completed by 567,781 and 301,717 individuals following dose one and dose two, and by 14,984 unvaccinated participants. In the multivariate analysis, health events within a week following vaccination were higher among vaccinated individuals compared to controls, with risk ratios (RR) ranging from 2.3 [95% Confidence Interval (C·I.) 2.1 to 2.6] for the first dose of BNT162b2 to 7 [95% C·I. 6.3 to 7.8] for the second consecutive dose of mRNA-1273. Common symptoms included fatigue/malaise, headache, fever and joint pain, and most were self-limited. Health events requiring an ED visit or hospitalization were significantly increased after the first dose of mRNA-1273 (RR 2.1 [95% C.I. 1.5 to 3.1]) or the second consecutive dose of mRNA-1273 (RR 2 [95% C.I. 1.3 to 2.9]). In summary, self-limited health events were more common in the week following vaccination with a first or second dose of an mRNA COVID-19 vaccine, compared with controls, with the highest frequency occurring after a second dose of mRNA-1273. Health events requiring an ED visit or hospitalization were more common in participants who received the mRNA-1273 vaccine, compared with controls. This difference was not observed for the BNT1262b2 vaccine.
引用
- Muller MP, Soe P, Shulha HP, et al. mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network. Vaccine. 2026. PMID: 42092317. doi:10.1016/j.vaccine.2026.128630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。